Viridian Therapeutics, Inc.\DE Quarterly Debt-to-equity in % from Q3 2017 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Viridian Therapeutics, Inc.\DE quarterly Debt-to-equity history and growth rate from Q3 2017 to Q2 2024.
  • Viridian Therapeutics, Inc.\DE Debt-to-equity for the quarter ending June 30, 2024 was 10.8 %, a 10.5% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 10.8 +1.02 +10.5% Jun 30, 2024
Q1 2024 10.9 +0.44 +4.21% Mar 31, 2024
Q4 2023 11.9 +1.44 +13.8% Dec 31, 2023
Q3 2023 11.7 +1.5 +14.8% Sep 30, 2023
Q2 2023 9.75 -1.25 -11.4% Jun 30, 2023
Q1 2023 10.5 +0.06 +0.58% Mar 31, 2023
Q4 2022 10.4 -1.08 -9.38% Dec 31, 2022
Q3 2022 10.2 -1.91 -15.8% Sep 30, 2022
Q2 2022 11 -6.1 -35.7% Jun 30, 2022
Q1 2022 10.4 -9.04 -46.5% Mar 31, 2022
Q4 2021 11.5 -13.5 -54% Dec 31, 2021
Q3 2021 12.1 -47.6 -79.7% Sep 30, 2021
Q2 2021 17.1 -45.5 -72.7% Jun 30, 2021
Q1 2021 19.4 -38.5 -66.4% Mar 31, 2021
Q4 2020 25 -27.5 -52.3% Dec 31, 2020
Q3 2020 59.6 +19.5 +48.5% Sep 30, 2020
Q2 2020 62.6 +30.4 +94.6% Jun 30, 2020
Q1 2020 57.9 +31.3 +117% Mar 31, 2020
Q4 2019 52.5 +29.1 +124% Dec 31, 2019
Q3 2019 40.2 +15.8 +65% Sep 30, 2019
Q2 2019 32.2 +8.96 +38.6% Jun 30, 2019
Q1 2019 26.7 +3.15 +13.4% Mar 31, 2019
Q4 2018 23.4 -0.88 -3.62% Dec 31, 2018
Q3 2018 24.3 -30.3 -55.5% Sep 30, 2018
Q2 2018 23.2 Jun 30, 2018
Q1 2018 23.5 Mar 31, 2018
Q4 2017 24.3 Dec 31, 2017
Q3 2017 54.7 Sep 30, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.